Latest facts presented at the European Respiratory Society (ERS) congress demonstrate the efficacy of budesonide/formoterol continuation and reliever therapy (Symbicort SMART*) in reducing exacerbations and improving daily asthma control in patients with uncontrolled asthma. This additionally illustrates the additional benefits of this new asthma management come near (one inhaler for both preservation and for relief) finished traditional treatment regimens; salmeterol/fluticasone and budesonide/formoterol advantage secluded reliever medication in achieving reductions in exacerbations.

This data, from farther analyses of the COMPASS study, show that budesonide/formoterol used as both maintenance and reliever therapy is more effective in reducing exacerbations in patients with average or on the top of usually need object of reliever medication than settled doses of salmeterol/fluticasone or budesonide/formoterol plus split reliever medication.1 A further post hoc analysis of this determined population from COMPASS2 demonstrates that in patients symptomatic on heinous doses of inhaled corticosteroids, budesonide/formoterol employed as both maintenance and reliever therapy reduced the be worthy of of exacerbations by 57 percent when compared to higher, fixed stipend doses of salmeterol/fluticasone ( p≤0.03) plus group reliever medication, and 42 percent compared to higher fixed maintenance doses of budesonide/formoterol increased by branch reliever medication.

“These data show that budesonide/formoterol maintenance and reliever therapy is more effective in reducing exacerbations quits in patients with rotten controlled asthma - demonstrated by the presence of asthma symptoms or increased need for reliever therapy - than traditional approaches such as increased doses of ICS/LABA,” commented Piotr Kuna, President of the Smoothness Group of Allergology and one of the authors of the COMPASS observe. “This unusual approach enables patients to healing the underlying cause of asthma each chance they capitalize on their inhaler which may assist patients to achieve wiser day-to-age dominate of their asthma.”

Budesonide/formoterol contribution and reliever group therapy is the first treatment approach to provide patients with both asthma maintenance and reliever therapy together in one inhaler; budesonide (an anti-inflammatory group therapy that acts within hours) and formoterol (a bronchodilator that is both fast in effect and dream of lasting). With budesonide/formoterol maintenance and reliever remedial programme, patients treat the underlying irritation of their airways with every inhalation, whether used as a replacement for maintenance or symptom relief. This treatment approach is given an Confirmation A rating in the recently updated (November 2006) Global Initiative for Asthma’s (GINA) Wide-ranging Strategy to save Asthma Management and Prevention.3

Data from the IN THE LEAD study,4 also presented at ERS, demonstrate that budesonide/formoterol used as both sustentation and reliever therapy had a numerically further risk of a first exacerbation (p=0.12) and was more goods in reducing the incidence of asthma exacerbations by 21 percent (p=0.039) compared to the highest approved administer of salmeterol/fluticasone plus separate reliever medication. In addition, the deserve of hospitalisations/emergency margin visits decreased by 31 percent (p=0.046) using budesonide/formoterol maintenance and reliever therapy.4 Similar improvements in daily asthma control were seen between groups, with lower use of inhaled corticosteroids (ICS) in the budesonide/formoterol maintenance and reliever therapy society. Figures from a clinical safety materials review, also presented at ERS, further add to the indication supporting the use of formoterol as a elongated-acting beta-agonist (LABA) in asthma treatment.5

An analysis of the AHEAD study also showed that budesonide/formoterol maintenance and reliever therapy provides a more fetch-effective government approach to asthma treatment than high-portion salmeterol/fluticasone, lowering the direct healthcare costs by €2330 per 100 patients.6

“Updated guidelines issued by the Universal Initiative for Asthma focus strongly on the importance of achieving fair control of asthma symptoms, such as exacerbations. The information presented at ERS add to a strong bank of clinical evidence to advocate the use of budesonide/formoterol maintenance and reliever therapy and mention that this new management approach could lift physicians and patients to deal with the recommendations of GINA,” concluded Jean Bousquet, Professor of Respiratory Prescription, Montpellier University, Redactor of Allergy and Chairman of the Global Affinity against Chronic Respiratory Diseases (GARD).

AstraZeneca is a foremost international healthcare business engaged in the research, development, manufacture and marketing of prescription pharmaceuticals and the supply of healthcare services. It is one of the world’s leading pharmaceutical companies with healthcare sales of $26.47 billion and outstanding positions in sales of gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infection products. AstraZeneca is listed in the Dow Jones Sustainability Token (Global) as sufficiently as the FTSE4 Good Forefinger.

References

1. Buhl R, Kuna P on behalf of the COMPASS investigators; Does the choosing of ICS/LABA regimen pressurize exacerbation rates in asthma patients with high as-needed buy? Resume presented at ERS 2007

2. Kuna P, Peters M, Buhl R for the COMPASS review investigators; Budesonide/formoterol for maintenance and relief vs. higher administer ICS/LABA cure: Outcomes in patients symptomatic on turned on-portion inhaled corticosteroids (HDICS). Survey presented at ERS 2007

3. Extensive Initiative recompense Asthma. Epidemic strategy with a view asthma management and blocking 2006. To hand from http://www.ginasthma.org Accessed July 13th 2007

4. Bousquet J and Boulet L-P payment the UP AHEAD Investigators; Budesonide/formoterol as maintenance and reliever therapy in uncontrolled asthma compared with altered consciousness dosage salmeterol/fluticasone: The AHEAD dead ringer-blind weigh. Abstract presented at ERS 2007

5. Sears, M.R. et al; Safety of formoterol in asthma trials. Abstract presented at ERS 2007

6. Bousquet J, Miravitlles M and Wiren A; Budesonide/formoterol provides better efficacy at a debase or similar outlay as compared to high-dose salmeterol/fluticasone treatment. Abstract presented at ERS 2007

* Symbicort SMART is a trade mark of the AstraZeneca group of companies

COMPASS - extravagant as-needed use1

- Using the data from the COMPASS study1, the efficacy of budesonide/formoterol continuation and reliever therapy was compared with fixed doses of budesonide/formoterol and salmeterol/fluticasone plus separate reliever psychoanalysis in patients with varying levels of let go free use

Results showed that:

- Budesonide/formoterol maintaining and reliever therapy is more effective in patients with usually or in the sky so so be in want of in behalf of reliever therapy

- Salmeterol/fluticasone deplete was associated with an increased neediness for danger treatment compared to both budesonide/formoterol regimens

COMPASS - pre-study expensive ICS2

- An analysis of the subgroup of patients (n=525) from the COMPASS study1 using gamy-measure inhaled corticosteroids (HDICS) at study entry-way

- The subanalysis was conducted to asses the efficacy of budesonide/formoterol maintenance and reliever remedy in symptomatic patients on HDICS compared to higher fixed-doses of budesonide/formoterol 320/9 mcg request and salmeterol/fluticasone 250/50 plus separate reliever medication

Results showed that:

- Budesonide/formoterol maintenance and reliever remedy significantly reduced the assess of exacerbations by 42% and 57% compared to higher living doses of budesonide/formoterol and salmeterol/fluticasone separately plus reliever therapy

- Support c substance annualised exacerbation rates per 100 patients were 32, 55 and 75 with budesonide/formoterol perpetuation and reliever group therapy, budesonide/formoterol or salmeterol/fluticasone, respectively

- Almost identical trends in elect of budesonide/formoterol maintenance and reliever therapy were seen in hospitalisations/emergency cell visits

- Patients treated with budesonide/formoterol maintenance and reliever therapy hardened ≈25% less ICS (beclomethasone equivalent) than patients in the fixed dispense groups

The AHEAD Study4,6

- AHEAD was conducted to assess whether budesonide/formoterol used as both maintenance and reliever therapy is more effective in improving asthma control compared to sustained enormous-dose salmeterol/fluticasone 50/500 mcg bid gain separate reliever medication

Results showed that:

- The peril of having a first exacerbation is numerically debase for budesonide/mormoterol maintenance and reliever therapy but not significantly different between the groups (p=0.12).

- Budesonide/formoterol maintenance and reliever therapy is more effective in reducing the degree of asthma exacerbations than sustained high-prescribe salmeterol/fluticasone (S/F) plus separate reliever medication

- Budesonide/formoterol maintenance and reliever therapy provides a more effective asthma treatment, at a lower or similar cost, than high-class-portion S/F

- Budesonide/formoterol maintenance and reliever psychotherapy reduced exacerbation rates by 21% compared to S/F-treatment and reduced the rate of hospitalisations/ER visits by 31%

- Similar improvements in daily asthma govern were seen between groups with lower use of inhaled corticosteroids in the budesonide/formoterol subvention and reliever therapy group (BDP equivalents5 1238 ug/day vs. 2000 ug /day in the S/F plus reliever group, p

Filed under: Category Uncategorized | Tags: by charterror